|Videos|January 7, 2016

Dr. Piyush Agarwal on Recognizing, Diagnosing, and Treating Penile Cancer

Agarwal says patients whose penile cancer does not spread to their lymph nodes have a 95% chance of survival over the course of 5 years, while survival for those whose cancer spreads to their lymph nodes is significantly less.

Piyush Agarwal, MD, Center for Cancer Research National Cancer Institute, discusses the difference between penile cancer confined to the penis and cancer that spreads to the lymph nodes. Agarwal says patients whose penile cancer does not spread to their lymph nodes have a 95% chance of survival over the course of 5 years, while survival for those whose cancer spreads to their lymph nodes is significantly less.

Stay up to date on practice-changing data in community practice.

Dr. Piyush Agarwal on Recognizing, Diagnosing, and Treating Penile Cancer

Related Content

Long-Term Outcomes Offer Reassurance on Quadruplet Use in Transplant-Ineligible NDMM

Allostatic Load Emerges as a Risk Marker for Early-Onset Cancer

Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC

Velzatinib Aims For Future Direct Comparison With Imatinib in GIST

ASCO 2026 GU Cancer Highlights: Beyond the LBAs

Latest CME

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Washington

Updates from Chicago: Oral SERDs in HR+/HER2- Metastatic Breast Cancer – What the Latest Data Really Tell Us

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Wyoming & Montana

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – North Carolina

Iowa Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Nevada Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | The Arizona Clinical Oncology Society

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Missouri Oncology Society

Kansas Society of Clinical Oncology

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Clarifying Novel Treatment Pathways in HER2+ Breast Cancer – Rhode Island

Louisiana Oncology Society

Missouri Oncology Society

New Mexico Society of Clinical Oncology

25th Annual International Congress on the Future of Breast Cancer® East

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

25th Annual International Congress on the Future of Breast Cancer® West

Wisconsin Association of Hematology and Oncology

Indiana Oncology Society

Rhode Island Oncology Society

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Breaking Down the Rationale for Targeting TROP2 in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Establishing the Rationale for ADC and ICI Combinations in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

24th Annual International Congress on the Future of Breast Cancer® East

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

9th Annual School of Nursing Oncology™

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

ASCO 2026 GU Cancer Highlights: Beyond the LBAs

Dr Cloughesy on Extended Follow-Up Data for Vorasidenib in IDH1/2 Mutant Glioma

Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC

FDA Grants Priority Review to Giredestrant for ER+/HER2- Breast Cancer

Targeting the IL-2 Pathway to Overcome Immunotherapy Resistance in Melanoma